The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 Pandemic

被引：89

作者：

Won, Jung-Hyun ^{[1
,2
]}

Lee, Howard ^{[1
,2
,3
,4
,5
]}

机构：

[1] Seoul Natl Univ, Grad Sch Convergence Sci & Technol, Dept Mol Med & Biopharmaceut Sci, Seoul 03080, South Korea

[2] Seoul Natl Univ, Grad Sch Convergence Sci & Technol, Ctr Convergence Approaches Drug Dev, Seoul 03080, South Korea

[3] Seoul Natl Univ, Dept Clin Pharmacol & Therapeut, Coll Med, Seoul 03080, South Korea

[4] Seoul Natl Univ Hosp, Dept Clin Pharmacol & Therapeut, Seoul 03080, South Korea

[5] Seoul Natl Univ, Grad Sch Convergence Sci & Technol, Dept Transdisciplinary Studies, Seoul 16229, South Korea

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2020年 / 21卷 / 24期

基金：

新加坡国家研究基金会;

关键词：

SARS-CoV-2; COVID-19; drug repositioning; vaccine; public health crisis; RESPIRATORY SYNDROME; CORONAVIRUS; CHLOROQUINE; VIRUS; LOPINAVIR/RITONAVIR; EPIDEMIOLOGY; TECHNOLOGIES; EFFICACY; TRIAL; SARS;

D O I：

10.3390/ijms21249775

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Since the outbreak of coronavirus disease 2019 (COVID-19) was first identified, the world has vehemently worked to develop treatments and vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at an unprecedented speed. Few of the repositioned drugs for COVID-19 have shown that they were efficacious and safe. In contrast, a couple of vaccines against SARS-CoV-2 will be ready for mass rollout early next year. Despite successful vaccine development for COVID-19, the world will face a whole new set of challenges including scale-up manufacturing, cold-chain logistics, long-term safety, and low vaccine acceptance. We highlighted the importance of knowledge sharing and collaboration to find innovative answers to these challenges and to prepare for newly emerging viruses.

引用

页码：1 / 17

页数：17

共 132 条

[11]

AstraZeneca, FDA AUTH REST COVID

[12]

AstraZeneca, AZD1222 VACC MET PRI

[13]

AstraZeneca, U OXF POT COVID 19 V

[14] Remdesivir for the Treatment of Covid-19-Final Report [J].

Beigel, John H. ;

Tomashek, Kay M. ;

Dodd, Lori E. ;

Mehta, Aneesh K. ;

Zingman, Barry S. ;

Kalil, Andre C. ;

Hohmann, Elizabeth ;

Chu, Helen Y. ;

Luetkemeyer, Annie ;

Kline, Susan ;

de Castilla, Diego Lopez ;

Finberg, Robert W. ;

Dierberg, Kerry ;

Tapson, Victor ;

Hsieh, Lanny ;

Patterson, Thomas F. ;

Paredes, Roger ;

Sweeney, Daniel A. ;

Short, William R. ;

Touloumi, Giota ;

Lye, David Chien ;

Ohmagari, Norio ;

Oh, Myoung-don ;

Ruiz-Palacios, Guillermo M. ;

Benfield, Thomas ;

Faetkenheuer, Gerd ;

Kortepeter, Mark G. ;

Atmar, Robert L. ;

Creech, C. Buddy ;

Lundgren, Jens ;

Babiker, Abdel G. ;

Pett, Sarah ;

Neaton, James D. ;

Burgess, Timothy H. ;

Bonnett, Tyler ;

Green, Michelle ;

Makowski, Mat ;

Osinusi, Anu ;

Nayak, Seema ;

Lane, H. Clifford .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (19) :1813-1826

[15]

BioRender, PROP THER TREATM COV

[16] Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection A Randomized Clinical Trial [J].

Borba, Mayla Gabriela Silva ;

Val, Fernando Fonseca Almeida ;

Sampaio, Vanderson Souza ;

Alexandre, Marcia Almeida Araujo ;

Melo, Gisely Cardoso ;

Brito, Marcelo ;

Mourao, Maria Paula Gomes ;

Brito-Sousa, Jose Diego ;

Baia-da-Silva, Djane ;

Guerra, Marcus Vinitius Farias ;

Hajjar, Ludhmila Abrahao ;

Pinto, Rosemary Costa ;

Balieiro, Antonio Alcirley Silva ;

Pacheco, Antonio Guilherme Fonseca ;

Santos, James Dean Oliveira, Jr. ;

Naveca, Felipe Gomes ;

Xavier, Mariana Simao ;

Siqueira, Andre Machado ;

Schwarzbold, Alexandre ;

Croda, Julio ;

Nogueira, Mauricio Lacerda ;

Romero, Gustavo Adolfo Sierra ;

Bassat, Quique ;

Fontes, Cor Jesus ;

Albuquerque, Bernardino Claudio ;

Daniel-Ribeiro, Claudio-Tadeu ;

Monteiro, Wuelton Marcelo ;

Lacerda, Marcus Vinicius Guimaraes .

JAMA NETWORK OPEN, 2020, 3 (04) :E208857

[17] A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 [J].

Boulware, David R. ;

Pullen, Matthew F. ;

Bangdiwala, Ananta S. ;

Pastick, Katelyn A. ;

Lofgren, Sarah M. ;

Okafor, Elizabeth C. ;

Skipper, Caleb P. ;

Nascene, Alanna A. ;

Nicol, Melanie R. ;

Abassi, Mahsa ;

Engen, Nicole W. ;

Cheng, Matthew P. ;

LaBar, Derek ;

Lother, Sylvain A. ;

MacKenzie, Lauren J. ;

Drobot, Glen ;

Marten, Nicole ;

Zarychanski, Ryan ;

Kelly, Lauren E. ;

Schwartz, Ilan S. ;

McDonald, Emily G. ;

Rajasingham, Radha ;

Lee, Todd C. ;

Hullsiek, Kathy H. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (06) :517-525

[18] The process development challenge for a new vaccine [J].

Buckland, BC .

NATURE MEDICINE, 2005, 11 (04) :S16-S19

[19] The Russian vaccine for COVID-19 [J].

Burki, Talha Khan .

LANCET RESPIRATORY MEDICINE, 2020, 8 (11) :E85-E86

[20] Darunavir: A second-generation protease inhibitor [J].

Busse, Kristin H. S. ;

Penzak, Scott R. .

AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2007, 64 (15) :1593-1602

← 1 2 3 4 5 6 7 8 9 10 →